Viswanath ANI - Search Results

1

Novel potent blockers for TWIK-1/TREK-1 heterodimers as potential antidepressants.

Lee EH, Park JE, Gotina L, Han YE, Viswanath ANI, Yoo S, Moon B, Hwang JY, Park WK, Cho Y, Song C, Min SJ, Hwang EM, Lee H, Pae AN, Roh EJ, Oh SJ. Lee EH, et al. Among authors: viswanath ani. Biomed Pharmacother. 2023 Sep;165:115139. doi: 10.1016/j.biopha.2023.115139. Epub 2023 Jul 15. Biomed Pharmacother. 2023. PMID: 37454597 Free article.

2

Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.

Viswanath AN, Jung SY, Hwang EM, Park KD, Lim SM, Min SJ, Cho YS, Pae AN. Viswanath AN, et al. Chem Biol Drug Des. 2016 Dec;88(6):807-819. doi: 10.1111/cbdd.12810. Epub 2016 Jul 27. Chem Biol Drug Des. 2016. PMID: 27346364

3

Resistance by allostery: a novel perspective for eg5-targeted drug design.

Viswanath AN, Pae AN. Viswanath AN, et al. J Med Chem. 2013 Aug 22;56(16):6314-6. doi: 10.1021/jm401071u. Epub 2013 Jul 30. J Med Chem. 2013. PMID: 23899248

4

Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.

Elkamhawy A, Farag AK, Viswanath AN, Bedair TM, Leem DG, Lee KT, Pae AN, Roh EJ. Elkamhawy A, et al. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5147-54. doi: 10.1016/j.bmcl.2015.10.003. Epub 2015 Oct 9. Bioorg Med Chem Lett. 2015. PMID: 26475520

5

In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level.

Park I, Hwang YJ, Kim T, Viswanath ANI, Londhe AM, Jung SY, Sim KM, Min SJ, Lee JE, Seong J, Kim YK, No KT, Ryu H, Pae AN. Park I, et al. Among authors: viswanath ani. J Comput Aided Mol Des. 2017 Oct;31(10):877-889. doi: 10.1007/s10822-017-0052-3. Epub 2017 Sep 6. J Comput Aided Mol Des. 2017. PMID: 28879500

6

Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).

Elkamhawy A, Viswanath AN, Pae AN, Kim HY, Heo JC, Park WK, Lee CO, Yang H, Kim KH, Nam DH, Seol HJ, Cho H, Roh EJ. Elkamhawy A, et al. Eur J Med Chem. 2015 Oct 20;103:210-22. doi: 10.1016/j.ejmech.2015.08.001. Epub 2015 Aug 4. Eur J Med Chem. 2015. PMID: 26355532

7

In silico-designed novel non-peptidic ABAD L_D hot spot mimetics reverse Aβ-induced mitochondrial impairments in vitro.

Viswanath ANI, Kim T, Jung SY, Lim SM, Pae AN. Viswanath ANI, et al. Chem Biol Drug Des. 2017 Dec;90(6):1041-1055. doi: 10.1111/cbdd.13065. Epub 2017 Jul 27. Chem Biol Drug Des. 2017. PMID: 28660722

8

GRP78-targeted in-silico virtual screening of novel anticancer agents.

Viswanath ANI, Lim JW, Seo SH, Lee JY, Lim SM, Pae AN. Viswanath ANI, et al. Chem Biol Drug Des. 2018 Aug;92(2):1555-1566. doi: 10.1111/cbdd.13322. Epub 2018 May 31. Chem Biol Drug Des. 2018. PMID: 29718569

9

Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.

Hayat F, Viswanath AN, Pae AN, Rhim H, Park WK, Choo HY. Hayat F, et al. Bioorg Med Chem. 2015 Mar 15;23(6):1313-20. doi: 10.1016/j.bmc.2015.01.032. Epub 2015 Jan 24. Bioorg Med Chem. 2015. PMID: 25684421

10

Psoralidin, a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia.

Liu X, Nam JW, Song YS, Viswanath AN, Pae AN, Kil YS, Kim HD, Park JH, Seo EK, Chang M. Liu X, et al. Bioorg Med Chem Lett. 2014 Mar 1;24(5):1403-6. doi: 10.1016/j.bmcl.2014.01.029. Epub 2014 Jan 20. Bioorg Med Chem Lett. 2014. PMID: 24507928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters